Discounts and patient assistance programs may be available for Praluent (alirocumab), a PCSK9 inhibitor used to lower cholesterol. Eligibility for these programs often depends on factors such as insurance status and income level.
How can I get a Praluent discount?
Praluent offers savings cards and co-pay assistance programs for eligible patients. These programs can help reduce out-of-pocket costs for those with commercial or private insurance. For example, the Praluent MyWay Savings Card can lower the cost for eligible patients to as little as $0 for a 12-month supply [1]. Information on these programs is typically available through the Praluent manufacturer's website or by speaking with a healthcare provider.
Are there Praluent patient assistance programs?
For patients who are uninsured or underinsured, Praluent may have a patient assistance program. These programs aim to provide medication at a reduced cost or free of charge to individuals who meet specific financial criteria. Details regarding eligibility and application processes for such programs can be found by contacting the Praluent manufacturer or through healthcare advocacy groups.
What is the typical cost of Praluent without insurance?
The cost of Praluent without insurance can vary significantly. Without any discounts or assistance programs, the retail price for a 30-day supply of Praluent can be several hundred dollars. This highlights the importance of exploring available savings options and patient assistance programs for individuals without prescription drug coverage.
When does Praluent patent exclusivity expire?
The patent landscape for Praluent is complex and involves multiple patents covering the drug substance, methods of use, and manufacturing. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for understanding when generic or biosimilar versions of Praluent might become available. Patent expirations are staggered, with some key patents expiring in the coming years [2]. For example, certain patents related to the active ingredient are expected to expire around 2026-2028, while others may extend further [2].
Who are Praluent's main competitors?
Praluent competes with other PCSK9 inhibitors, such as Repatha (evolocumab). Both drugs work by targeting the PCSK9 protein to lower LDL cholesterol levels and are used in patients with high cholesterol who cannot achieve their goals with statins alone [3]. Other cholesterol-lowering medications, including statins and ezetimibe, also represent competitive options in the broader cardiovascular market.
---
1. Praluent Savings Card. Praluent. Accessed October 26, 2023.
2. DrugPatentWatch. Praluent. Accessed October 26, 2023. https://drugpatentwatch.com/
3. Praluent (alirocumab) Prescribing Information. Sanofi. Accessed October 26, 2023.